Results 181 to 190 of about 37,898 (281)

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF [PDF]

open access: gold, 2023
Qianyu Fu   +7 more
openalex   +1 more source

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients [PDF]

open access: gold, 2023
Alfonso Campanile   +12 more
openalex   +1 more source

THERMODILUTION CARDIAC INDEX IS MORE STRONGLY ASSOCIATED WITH 1-YEAR OUTCOMES THAN MEASURED FICK CARDIAC INDEX IN PATIENTS WITH HFREF: IS IT TIME TO ABANDON THE GOLD STANDARD?

open access: bronze, 2022
Nishant Jain   +8 more
openalex   +1 more source

Role of N-terminal pro-B type natriuretic peptide as a predictor of poor outcomes in patients with HFrEF receiving primary prevention implantable cardioverter-defibrillator therapy: a systematic review and dose–response meta-analysis [PDF]

open access: gold, 2023
Hawani Sasmaya Prameswari   +10 more
openalex   +1 more source

P240 SHORT–TERM EFFECT OF SGLT2I ON ECHOCARDIOGRAPHIC PARAMETERS IN HFREF PATIENTS TREATED WITH ARNI

open access: bronze, 2022
Samanta Mazzetti   +9 more
openalex   +1 more source

CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF [PDF]

open access: gold, 2023
Annika Weidenhammer   +13 more
openalex   +1 more source

Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.

open access: yesJournal of the American College of Cardiology, 2019
M. Zile   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy